Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new class of glucose-lowering agents which have changed the landscape of diabetes therapy, due to their remarkable cardiorenal protective properties. The attack of severe acute respiratory syndrome coronavirus 2 on the heart and kidneys share...

Descripción completa

Detalles Bibliográficos
Autores principales: Koufakis, Theocharis, Pavlidis, Antonis N., Metallidis, Symeon, Kotsa, Kalliopi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942520/
https://www.ncbi.nlm.nih.gov/pubmed/33751323
http://dx.doi.org/10.1007/s11096-021-01256-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942520/
https://www.ncbi.nlm.nih.gov/pubmed/33751323
http://dx.doi.org/10.1007/s11096-021-01256-9

Ejemplares similares